Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features

Dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA.R-EPOCH) is used for upfront treatment of high-risk diffuse large B cell lymphoma (DLBCL). In this study, we compared the outcomes in patients with high-risk DLBCL who received frontline rituximab, cyco...

Descripción completa

Detalles Bibliográficos
Autores principales: Dholaria, Bhagirathbhai, Vanegas, Yenny Alejandra Moreno, Diehl, Nancy, Spaulding, Aaron C., Visscher, Sue, Tun, Han W., Ailawadhi, Sikander, Vishnu, Prakash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Atlantis Press 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432333/
https://www.ncbi.nlm.nih.gov/pubmed/34595452
http://dx.doi.org/10.2991/chi.d.200410.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432333/
https://www.ncbi.nlm.nih.gov/pubmed/34595452
http://dx.doi.org/10.2991/chi.d.200410.001

Ejemplares similares